Note 15 - Fair Value Disclosures (Tables)

3 Months Ended

Mar. 31, 2021

Notes Tables

Fair Value, by Balance Sheet Grouping [Table Text Block]

	Fair Value Measured at Reporting Date Using
	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At March 31, 2021:
Cash and cash equivalents	$	780	$	-	$	780	$	-	$	780
Other receivables	$	71,269	$	-	$	-	$	71,269	$	71,269
Note receivable – CEN Biotech Ukraine, LLC – related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to Emergence Global - related party	$	17,901	$	-	$	-	$	17,901	$	17,901
Advances to CEN Biotech Ukraine, LLC - related party	$	1,229,328	$	-	$	-	$	1,229,328	$	1,229,328
Loans payable	$	531,152	$	-	$	-	$	531,152	$	531,152
Loans payable – related parties	$	1,363,831	$	-	$	-	$	-	$	-
Patent acquisition liability	$	1,380,000	$	-	$	-	$	1,380,000	$	1,380,000
Convertible notes payable	$	6,851,275	$	-	$	-	$	7,977,476	$	7,977,476
Convertible notes payable – related parties	$	2,558,681	$	-	$	-	$	-	$	-

	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At December 31, 2020:
Cash and cash equivalents	$	1,908	$	-	$	1,908	$	-	$	1,908
Other receivables	$	113,999	$	-	$	-	$	113,999	$	113,999
Note receivable – CEN Biotech Ukraine, LLC – related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to Emergence Global - related party	$	17,901	$	-	$	-	$	17,901	$	17,901
Advances to CEN Biotech Ukraine, LLC - related party	$	1,179,328	$	-	$	-	$	1,179,328	$	1,179,328
Loans payable	$	527,379	$	-	$	-	$	527,379	$	527,379
Loans payable – related parties	$	1,363,354	$	-	$	-	$	-	$	-
Patent acquisition liability	$	1,380,000	$	-	$	-	$	1,380,000	$	1,380,000
Convertible notes payable	$	6,730,448	$	-	$	-	$	7,766,663	$	7,766,663
Convertible notes payable – related parties	$	2,558,681	$	-	$	-	$	-	$	-